Galderma Receives U.S. FDA Approval for Nemluvio (Nemolizumab) for Patients with Moderate-to-Severe
Ad hoc announcement pursuant to Art. 53 LR
Approximately 7% of people in the United States (U.S.) have atopic dermatitis
来源:
作者:
免责声明:中国新金融网所载文章、数据等内容仅代表作者个人观点,与中国新金融网无关,其陈述、观点仅供参考。 请读者自行考量,且风险自担。版权声明:中国新金融网所载文章部分来源网络,如若不允许转载,请联系我们,我们将及时撤除。